298 related articles for article (PubMed ID: 32536918)
1. Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses.
Stolk DA; de Haas A; Vree J; Duinkerken S; Lübbers J; van de Ven R; Ambrosini M; Kalay H; Bruijns S; van der Vliet HJ; de Gruijl TD; van Kooyk Y
Front Immunol; 2020; 11():990. PubMed ID: 32536918
[TBL] [Abstract][Full Text] [Related]
2. Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets.
Duinkerken S; Horrevorts SK; Kalay H; Ambrosini M; Rutte L; de Gruijl TD; Garcia-Vallejo JJ; van Kooyk Y
Theranostics; 2019; 9(20):5797-5809. PubMed ID: 31534520
[TBL] [Abstract][Full Text] [Related]
3. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
[TBL] [Abstract][Full Text] [Related]
4. Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.
Lameris R; Schneiders FL; de Gruijl TD; van der Vliet HJ
Methods Mol Biol; 2014; 1139():155-65. PubMed ID: 24619678
[TBL] [Abstract][Full Text] [Related]
5. NKT Cell-Driven Enhancement of Antitumor Immunity Induced by Clec9a-Targeted Tailorable Nanoemulsion.
Lam PY; Kobayashi T; Soon M; Zeng B; Dolcetti R; Leggatt G; Thomas R; Mattarollo SR
Cancer Immunol Res; 2019 Jun; 7(6):952-962. PubMed ID: 31053598
[TBL] [Abstract][Full Text] [Related]
6. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
Durgan K; Ali M; Warner P; Latchman YE
Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
[TBL] [Abstract][Full Text] [Related]
7. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.
Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F
J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009
[TBL] [Abstract][Full Text] [Related]
8. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
[TBL] [Abstract][Full Text] [Related]
9. Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141
Huang J; Zhou J; Ghinnagow R; Seki T; Iketani S; Soulard D; Paczkowski P; Tsuji Y; MacKay S; Cruz LJ; Trottein F; Tsuji M
Front Immunol; 2020; 11():2043. PubMed ID: 32973811
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
11. IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses.
Moreno M; Molling JW; von Mensdorff-Pouilly S; Verheijen RH; Hooijberg E; Kramer D; Reurs AW; van den Eertwegh AJ; von Blomberg BM; Scheper RJ; Bontkes HJ
J Immunol; 2008 Aug; 181(4):2446-54. PubMed ID: 18684935
[TBL] [Abstract][Full Text] [Related]
12. Effective stimulation of invariant natural killer T cells by oligomannose-coated liposomes.
Ishii M; Kojima N
Int Immunopharmacol; 2013 Apr; 15(4):685-92. PubMed ID: 23535021
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
14. In situ Delivery of Tumor Antigen- and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic Cells.
Boks MA; Bruijns SCM; Ambrosini M; Kalay H; van Bloois L; Storm G; Gruijl T; van Kooyk Y
J Invest Dermatol; 2015 Nov; 135(11):2697-2704. PubMed ID: 26083554
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro analyses of α-galactosylceramide uptake by conventional dendritic cell subsets using its fluorescence-labeled derivative.
Ushida M; Iyoda T; Kanamori M; Watarai H; Takahara K; Inaba K
Immunol Lett; 2015 Dec; 168(2):300-5. PubMed ID: 26481266
[TBL] [Abstract][Full Text] [Related]
16. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
[TBL] [Abstract][Full Text] [Related]
17. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
18. MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses.
Boks MA; Ambrosini M; Bruijns SC; Kalay H; van Bloois L; Storm G; Garcia-Vallejo JJ; van Kooyk Y
J Control Release; 2015 Oct; 216():37-46. PubMed ID: 26151293
[TBL] [Abstract][Full Text] [Related]
19. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.
Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA
Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371
[TBL] [Abstract][Full Text] [Related]
20. Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.
Schneiders FL; Huijts CM; Mantici A; Menks MA; Scotet E; Veerhuis R; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2015 May; 158(1):92-9. PubMed ID: 25796193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
